trending Market Intelligence /marketintelligence/en/news-insights/trending/d6Bn-fnGF5KDFWQFxGVLkA2 content esgSubNav
In This List

Acorda to appeal ruling invalidating multiple sclerosis drug patents

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Acorda to appeal ruling invalidating multiple sclerosis drug patents

Acorda Therapeutics Inc. plans to appeal the U.S. District Court of Delaware ruling that invalidated four U.S. patents related to its multiple sclerosis drug AMPYRA.

The court, meanwhile, upheld a patent related to the drug, which is set to expire in July 2018.

The U.S. Patent and Trademark Office had previously upheld these four patents which were challenged via the inter partes review process.